Background-Current treatment for acute myocardial infarction (AMI) focuses on reestablishing blood flow (reperfusion).
C urrent treatment for acute myocardial infarction (AMI) is aimed at limiting the duration of the ischemic period by disrupting the occlusion in the coronary artery. However, no therapeutic treatment is available to prevent reperfusion injury, which occurs after these interventions. 1, 2 We previously developed several isozyme-selective inhibitor and activator peptides of protein kinase C (PKC). 3 Recently, we found that treatment with a ␦PKC-selective inhibitor during ischemia/reperfusion reduced cardiac damage in isolated perfused rat hearts. 3, 4 Here, we show that the ␦PKC inhibitor prevented reperfusion injury in an in vivo porcine model of AMI.
Methods

Peptide Synthesis
The ␦PKC inhibitor peptide ␦V1-1 was synthesized and conjugated to Tat-derived peptide 5 via a cysteine S-S bond as described. 3 
In Vivo Local Occlusion, Peptide Delivery, and Pathological Assessment
We applied a balloon catheter into the mid left anterior descending coronary artery of female juvenile Yorkshire pigs (35 to 40 kg) under anesthesia (1% isoflurane) and inflated the balloon to produce a total occlusion for 30 minutes. The guide wire was removed, and Tat alone (Tat) or Tat-␦V1-1 conjugate (␦V1-1) was infused via the lumen of the balloon catheter only for the last 1 minute of ischemia (250 ng/kg, 1 mL/min). Left ventriculograms were performed to determine cardiac function. Hearts were harvested 4 hours or 5 days after ischemia. Double staining with Evans blue dye and TTC marked areas at risk for ischemia and infarcted areas, respectively, as described previously. 6 Troponin T levels in blood, as an indicator of cardiac cytolysis, were also determined after 24 hours of reperfusion.
Wedge biopsies of liver, spleen, lung and kidney were fixed in 10% buffered neutral formalin and embedded in paraffin, and 8-m-thick sections were stained with hematoxylin and eosin for pathological examination.
Biochemical Analysis of Porcine Cardiac Tissue
Heart tissues were taken after a 4-hour reperfusion. Ischemic tissues from the left anterior descending coronary artery territory and nonischemic tissues from the posterior wall were taken after marking of area at risk with Evans blue dye ( Figure 1A ). Lysates were probed for active caspase-3 (Cell Signaling) and inactive caspase-3 (Santa Cruz). Tissue lysates were also fractionated into soluble and particulate fractions as described, 7 and ␦PKC translocation was determined by Western blot analysis (100 g/lane) using anti-␦PKC antibodies (Santa Cruz).
Heart tissues were embedded in OCT compound, snap-frozen on dry ice, and sectioned (5 m). Cardiac myocytes were identified by ␣-actinin (Sigma) staining with a FITC secondary antibody (Molec- Figure 1 . Intracoronary delivery of ␦V1-1 reduced reperfusion injury. A, Representative pictures of TTC staining in infarcted hearts (TTC stains surviving tissues red, leaving infarcted areas white). Arrows indicate area at risk. Scheme indicates that tissue samples (green) for Western blot analyses and TUNEL staining were taken from area at risk (red) and nonischemic area (blue). B, Quantification of area at risk and infarct size. C, Analysis of troponin T levels in blood samples. D, ␦V1-1 inhibition of ischemia/reperfusion (I/R)-induced translocation. Data are quantified as percent translocation above control. E, Western blot analysis of caspase-3 cleavage (lower arrow). Data are quantified as percentage of cleaved caspase-3 of total caspase-3 (upper arrows). F, Cardiomyocytes are identified by anti-␣-actinin staining (blue), apoptotic nuclei by TUNEL (yellow), and nuclei by DAPI staining (green). Significance of differences between ␦V1-1-treated (nϭ12) and Tat-treated (nϭ8) hearts was *PϽ0.01. D, E, and F, *PϽ0.02, ␦V1-1 vs Tat; †PϽ0.02, ␦V1-1 vs control; nϭ3 for each group. ular Probe). TUNEL staining was carried out for detection of apoptotic cells (Roche), and nuclei were counterstained with DAPI (Sigma). TUNEL-positive nuclei were counted in a total of 1500 myocytes over several randomly selected fields and expressed as a percentage of the total number of nuclei. All animal studies were approved by Stanford's Institutional Animal Care and Use Committee.
NMR Spectroscopy
Relative changes in phosphorus metabolites during ischemia/reperfusion were measured in isolated perfused mouse hearts (C57BL/ 6X129sv) subjected to a 20-minute global ischemia followed by a 40-minute reperfusion by acquiring consecutive 31 P NMR spectra, as described. 8 Tat or ␦V1-1 (50 nmol/L) was perfused for the first 15 minutes of reperfusion.
Statistical Analysis
Data are expressed as meanϮSEM. Unpaired t tests for comparisons between 2 groups and 1-way factorial ANOVA with Bonferroni's test for multiple comparisons were used.
Results
␦V1-1 Reduces Reperfusion-Induced Cardiac Damage
Although the areas at risk for ischemic insult were similar between Tat-treated and ␦V1-1-treated pigs, ␦V1-1 treatment resulted in an Ϸ80% reduction in infarct size and an Ϸ85% reduction in troponin T level in the blood (Figure 1, A, B , and C). Importantly, ␦V1-1 treatment improved cardiac ejection fraction 30 minutes after reperfusion (53.3Ϯ1.7% versus 43.2Ϯ2.4% for ␦V1-1 versus control, respectively; PϽ0.003) and normalized it by 5 days after the onset of reperfusion (67.7Ϯ3.0% versus 57.4Ϯ3.0%, respectively; PϽ0.02).
[Ejection fraction before ischemia was the same for ␦V1-1-treated and control groups (68.7Ϯ1.6% versus 68.8Ϯ2.9%, respectively).] ␦V1-1 treatment also reduced the hypokinetic area by 50% (20.0Ϯ3.7% versus 38.9Ϯ1.9%, respectively; PϽ0.0003) 30 minutes after reperfusion and by 75% (7.3Ϯ2.5% versus 28.8Ϯ3.6%, respectively; PϽ0.0001) 5 days later as determined by Plus Plus (Sanders Data Systems) analysis of the left ventriculogram. As expected, 3,9 ischemia/ reperfusion-induced ␦PKC translocation (50% increase over basal) was completely inhibited by ␦V1-1 treatment in these hearts ( Figure 1D ), suggesting that ischemia/reperfusioninduced cardiac damage in vivo is mediated by ␦PKC.
Previous reports demonstrated that apoptosis is a component in the death of cardiomyocytes during reperfusion. 10 Indeed, conversion of the proapoptotic proenzyme caspase-3 to the active cleaved form 11 increased significantly after ischemia/reperfusion compared with nonischemic tissue (Figure 1E, lower arrow) . However, ␦V1-1 treatment greatly reduced caspase-3 activation. In addition, DNA fragmentation (assessed histologically by TUNEL staining 12 ) was decreased by 67% in ␦V1-1-treated hearts compared with Tat-treated hearts ( Figure 1F ). These results suggest that inhibition of ␦PKC translocation inhibits reperfusion injuryinduced apoptosis.
We assessed possible adverse effects induced by ␦V1-1. The injection of ␦V1-1 resulted in no acute changes in blood pressure, heart rate, or cardiac function (data from all animals used in this study; not shown). Moreover, there were no pathological findings in any tissue, including kidney, lung, liver, and spleen. Therefore, ␦V1-1 treatment does not seem to cause acute allergic reaction or other adverse effects.
␦V1-1 Improves Recovery of Myocardial ATP, Phosphocreatine, and Intracellular pH During Reperfusion
Using 31 P NMR in an ex vivo model of cardiac ischemia, we determined whether the immediate improvement in cardiac contractility observed in ␦V1-1-treated animals could be a result of improved metabolism of the myocardium. Treatment with ␦V1-1 during reperfusion ex vivo resulted in a significant improvement in functional recovery (Figure 2, A and B) . We showed that ATP levels decreased to Ϸ20% of the preischemic level and remained at this level for the duration of the experiment in Tat-treated hearts ( Figure 2C ). However, ATP levels recovered to Ϸ70% in ␦V1-1-treated hearts. ␦V1-1 treatment improves recovery of ATP levels and phosphocreatine levels and correction of intracellular pH during reperfusion. A, Functional recovery of rate-pressure product (left ventricular developed pressure ϫ heart rate) is expressed as a percentage of preischemic baseline. B, End-diastolic pressure (EDP) after a 40-minute reperfusion. C, D, and E, ATP, phosphocreatine (PCr), and intracellular pH levels during ischemia/reperfusion. For ATP and PCr, areas of spectral peaks were expressed as a percentage of peak areas of preischemic control for each heart. *PϽ0.05, ␦V1-1 vs Tat; nϭ5 for each group.
